RxDoctor Payments Data

Patrick Godwin, MD

Internal Medicine · Roxboro, NCNPI 1164483483

Payments from drug & device makers

$3,170in general payments, 2019–2025

Across 190 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$449
  • Novo Nordisk$410
  • Lilly USA, LLC$265
  • Otsuka America Pharmaceutical, Inc.$216
  • Pfizer$209
  • Boehringer Ingelheim$161
  • plus $1K from 32 others

What the payments were for

  • Food & beverage$3,158100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,170 in reported general payments places this provider in the 85th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$311,792
Medicare patients
498
Services billed
3,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide407$521,423
EliquisApixaban255$286,981
FarxigaDapagliflozin Propanediol200$176,591
JardianceEmpagliflozin115$101,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$89,299
LinzessLinaclotide82$80,476
MounjaroTirzepatide67$73,533
TrulicityDulaglutide33$37,076
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog32$31,499
MysolinePrimidone12$22,341
RexultiBrexpiprazole13$22,047
RybelsusSemaglutide20$21,266
XareltoRivaroxaban15$20,311
VraylarCariprazine Hcl14$19,599
MyrbetriqMirabegron22$18,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$410$542,688427 claims
PfizerEliquis$209$286,981255 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$133$201,789238 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta, Arexvy$38$133,477170 claims
AbbVieLinzess, Vraylar, Ubrelvy$449$115,652109 claims
Boehringer IngelheimJardiance, Tradjenta$161$112,140128 claims
Lilly USA, LLCMounjaro, Trulicity$265$110,610100 claims
Otsuka America Pharmaceutical, Inc.Rexulti$216$22,04713 claims
Johnson & JohnsonXarelto$113$20,31115 claims
MerckJanuvia$150$18,05422 claims
NovartisEntresto$20$16,77616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Roxboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →